Monday, October 17, 2011

Gilenya (Fingolimod) to be highlighted at ECTRIMS meeting Oct 19-22

This is awesome news! From what I read in this article, not only does Fingolimod reduce the relapse rate but it appears to also protect the brain from atrophy. I had heard hints of this before but it's expected to be backed by data gleaned from the very trial I was in (TRANSFORMS) when presented at the ECTRIMS meeting to take place today.

Basel, October 17, 2011 - Novartis will showcase data from 13 abstracts on fingolimod (Gilenya(®)), at the 5th Joint Triennial Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) taking place from 19-22 October in Amsterdam.
Novartis drug Gilenya® (fingolimod) has more than 20,000 patient-years of exposure and shows up to 71% reduction in annualized relapse rates in MS patients with highly active disease | Cision Wire: "Fingolimod 0.5 mg reduced the rate of brain atrophy, or brain volume loss, compared to interferon beta 1a IM over 12 months, irrespective of disease
activity prior to study start as shown in an analysis of the pivotal Phase III
TRANSFORMS study[3]. (Abstract P907)"

'via Blog this'

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.